Pridopidine
Sponsors
Ferrer Internacional S.A., Prilenia Therapeutics B.V., Prilenia, Merit E. Cudkowicz, MD
Conditions
Amyotrophic Lateral SclerosisHuntington DiseaseHuntington's DiseaseParkinson Disease
Phase 2
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
CompletedNCT01306929
Start: 2011-03-24End: 2018-01-05Updated: 2022-02-09
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
CompletedNCT02006472
Start: 2014-02-28End: 2016-07-07Updated: 2021-07-19
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
TerminatedNCT02494778
Start: 2015-09-24End: 2018-01-12Updated: 2021-09-17
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
TerminatedNCT03922711
Start: 2019-05-22End: 2020-07-22Updated: 2022-07-01
HEALEY ALS Platform Trial - Master Protocol
RecruitingNCT04297683
Start: 2020-06-14End: 2028-08-01Target: 1500Updated: 2026-05-14
HEALEY ALS Platform Trial - Regimen D Pridopidine
CompletedNCT04615923
Start: 2020-12-18End: 2022-07-14Updated: 2023-08-23
Phase 3
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
CompletedNCT04556656
Start: 2020-10-16End: 2024-03-21Updated: 2025-03-12
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
RecruitingNCT07322003
Start: 2026-02-01End: 2029-03-01Target: 500Updated: 2026-04-24
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
Not yet recruitingCTIS2025-524002-16-00
Target: 133Updated: 2026-04-20